RE:RE:RE:RE:RE:RE:RE:RE:RE:Polish Researchers Cite Rutherrin PDT for Brain CancerYou are spot on with your comments Dawg. With strong data in hand in a pivotal ph2, a regional licensing deal is exactly what this company should have been pursuing many months ago. Even with this latest disappointing placement the company is still currently on cash fumes, with a quarterly cash burn rate in the $1.1M range. The math just doesn't work if we assume forthcoming BTD by Q1. After holding shares for 6 or 7 years now I unfortunately share your disappointment with management. Do you know if they mentioned at the recent AGM whether they were even considering a regional deal?